By Michael Dabaie


Teva Pharmaceutical Industries Ltd. (TEVA) said the U.S. Food and Drug Administration approved AirDuo Digihaler Inhalation Powder.

That is a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application for information on inhaler use to people with asthma.

AirDuo Digihaler is indicated for the treatment of asthma in patients aged 12 and older.

The approval of AirDuo Digihaler is based on the review of the supplemental new drug application Teva submitted to the FDA.


Write to Michael Dabaie at


(END) Dow Jones Newswires

July 15, 2019 09:18 ET (13:18 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.